spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Central Precocious Puberty 

 HSMN NewsFeed - 12 May 2021
Centers for Medicare and Medicaid Services (CMS) Issues Permanent J-Code for Tolmar's FENSOLVI(R) Effective July 1, 2021
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 4 May 2020
FDA Approves FENSOLVI(R) (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jun 2017
Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP)
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 May 2015
Debiopharm International SA Announces Phase III Positive Results for Triptorelin 6-month Formulation in the Management of Central Precocious Puberty (CPP)
Biopharmaceuticals
 HSMN NewsFeed - 15 Jul 2010
Endo Pharmaceuticals Completes Acquisition of HealthTronics, Inc.
Biopharmaceuticals Devices Mergers & Acquisitions
 HSMN NewsFeed - 6 May 2010
HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals
Devices Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Mar 2010
Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Oct 2009
Endo Pharmaceuticals Gives Update on Regulatory Status of FORTESTA(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2009
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jul 2009
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 28 Apr 2009
Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2009
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jan 2009
Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Sep 2008
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
Biopharmaceuticals Licensing
 HSMN NewsFeed - 30 Jun 2008
Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Jun 2008
Indevus Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2008
Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2008
Indevus Pharmaceuticals Licenses Canadian Rights for SANCTURA XR(TM) to Allergan, Inc.
Biopharmaceuticals Licensing Urology
 HSMN NewsFeed - 3 Mar 2008
Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2008
Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2007
FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 28 Aug 2007
Indevus Announces Submission of New Drug Application
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 17 Aug 2007
Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Aug 2007
Indevus Announces FDA Approval of SANCTURA(R) XR
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 29 Jun 2007
Indevus Appoints Industry Veteran Kurt Lewis as Senior Vice President Sales & Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jun 2007
Indevus Announces Launch of SUPPRELIN(R) LA for Central Precocious Puberty
Biopharmacceuticals
 HSMN NewsFeed - 7 Jun 2007
Indevus Reports Positive Data From Phase III NEBIDO(R) Trial
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2007
Indevus Announces Authorization for Approval of VANTAS(R) in Selected European Countries
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 May 2007
Indevus Announces FDA Approval of SUPPRELIN(R)-LA
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Apr 2007
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 19 Apr 2007
Indevus Announces Submission of Supplemental NDA to Reintroduce VALSTAR(R) to Treat Bladder Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 26 Mar 2007
Indevus Reports That Interim Review of NEBIDO(R) Phase III Data Indicates Trial Is Likely to Meet Primary Endpoints
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 12 Dec 2006
Indevus Pharmaceuticals to Acquire Valera Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 May 2006
Valera Pharmaceuticals Appoints Jeremy D. Middleton To The Position Of Vice President, Business Development
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
Central Precocious Puberty
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.